SNSrivatsava Naidu

Srivatsava Naidu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Srivatsava Naidu has a total of 38 co-authors. Here are the top co-authors by number of shared publications:

  • Mansi Sharma

    Department of Biomedical Engineering, Indian Institute of Technology Ropar

    4 shared publications
  • Sheetanshu Saproo

    Department of Biomedical Engineering, Indian Institute of Technology Ropar, Rupnagar, India

    4 shared publications
  • Shashanka Shekhar Sarkar

    Department of Biomedical Engineering, Indian Institute of Technology Ropar, Rupnagar, India

    3 shared publications
  • Srikanth Karnati

    Institute of Anatomy and Cell Biology, University of Würzburg

    3 shared publications
  • Anand Gupta

    Department of Dentistry, Government Medical College and Hospital, Chandigarh, India

    2 shared publications
  • Arpita Karmakar

    Department of Biomedical Engineering, Indian Institute of Technology Ropar, Rupnagar, India

    2 shared publications

Latest Publications

  • Open Access

    SPRTN preserves RNA polymerase I transcription under genotoxic drug stress in lung adenocarcinoma

    by Mansi Sharma, Srikanth Karnati, Süleyman Ergün, Srivatsava Naidu

    Background: Hyperactivated RNA polymerase I (Pol I)-driven ribosomal DNA (rDNA) transcription sustains malignant growth and chemotherapy tolerance in lung adenocarcinoma (LUAD). Genotoxic chemotherapeutics such as doxorubicin and cisplatin preferentially damage rDNA by inducing DNA-protein crosslinks (DPCs), yet how tumor cells preserve Pol I transcriptional output under this damage remains poorly understood. Methods: We investigated SPRTN function in LUAD using complementary approaches spanning molecular, cellular, and in vivo levels, including DNA-protein crosslink isolation, chromatin immunoprecipitation, nascent RNA synthesis assays, apoptosis and invasion assays in SPRTN loss- and gain-of-function cell models, mouse xenograft studies, and transcriptomic analysis of clinical LUAD datasets. Results: SPRTN was enriched at the rDNA promoter, limited basal DPC accumulation, sustained Pol I transcriptional output, suppressed the p53-p21 nucleolar stress checkpoint, and promoted Pol I-dependent proliferation. Under doxorubicin or cisplatin treatment, SPRTN was recruited to G-quadruplex-rich rDNA promoters, a process associated with PARP-1 co-recruitment, and facilitated DPC resolution and transcriptional recovery. Catalytically inactive SPRTN failed to resolve rDNA-DPCs and restore Pol I output under both basal and drug-treated conditions. Doxorubicin- and cisplatin-resistant LUAD cells exhibited elevated SPRTN expression and enhanced rRNA synthesis relative to parental cells. SPRTN knockdown increased apoptotic response to doxorubicin and cisplatin, and co-inhibition of SPRTN and Pol I additively induced apoptosis in both parental and resistant cells. SPRTN further promoted Pol I-dependent migration and invasion. Transcriptomically, SPRTN was upregulated in LUAD, correlated with advanced disease stage and reduced overall survival, and was transcriptionally activated by ZEB1 and post-transcriptionally repressed by miR-195-5p. In vivo , SPRTN silencing reduced tumor burden and suppressed Pol I transcription, with further reduction upon doxorubicin treatment. Conclusion: These findings establish SPRTN as an rDNA-associated repair factor that couples genotoxic damage resolution to Pol I transcriptional resilience, defining the SPRTN-Pol I axis as a determinant of nucleolar homeostasis and therapeutic vulnerability in lung adenocarcinoma.

  • Open Access

    NSH76: a selective inhibitor of RRN3 and RNA polymerase I transcription with potential for cancer therapy

    by Shashanka Shekhar Sarkar, Mansi Sharma, Arpita Karmakar, Kousar Jahan, Sheetanshu Saproo, Soumojit Biswas, Sakshi Nautiyal, Ipsita Roy, P. V. Bharatam, Srivatsava Naidu

    Aberrant upregulation of RNA polymerase I (Pol I) transcription and its dedicated machinery plays a pivotal role in tumor progression and chemoresistance. RRN3, a Pol I-specific transcription initiation factor, is frequently overexpressed in malignancies contributing to oncogenic processes. Despite the therapeutic potential of Pol I transcription inhibition, existing inhibitors lack specificity and are associated with DNA damage, mutagenicity, and toxicity, limiting their clinical utility. To fully realize the potential of Pol I-targeted cancer therapies, selective Pol I transcription inhibitors with minimal off-target effects are essential. Molecular docking and virtual screening were conducted to identify ligands targeting RRN3. Biochemical and spectroscopic analyses validated the direct ligand-RRN3 binding. The mechanism of action of the ligand was investigated through biochemical, cellular and molecular assays. Functional studies assessed the effects of the ligand on cancer cell viability, clonogenicity, cell cycle progression, and apoptosis, in comparison to non-cancerous cells. The ligand efficacy was further evaluated in chemoresistant cancer cell lines and 3D tumor spheroid models. Genotoxicity and mutagenicity were assessed using DNA damage and mutagenicity assays. We demonstrate that (N-(1-amidino-2-thiourea-alkyl-7-chloroquinoline-4-amine)) (NSH76) selectively inhibits Pol I transcription by disrupting the Pol I pre-initiation complex at the rDNA promoter through direct RRN3 binding. Notably, NSH76 does not affect cMyc expression, a Pol II-driven transcript, confirming its specificity. NSH76 preferentially inhibits Pol I transcription in cancer cells with high RRN3 expression, while sparing non-cancerous cells with low RRN3 levels. Functionally, NSH76 exhibits potent antiproliferative activity against cancer cells, with minimal impact on non-cancerous cells. NSH76 induces cell cycle arrest, suppresses clonogenicity, and significantly enhances apoptosis in cancer cells, including cisplatin- and doxorubicin-resistant cell lines. These effects are recapitulated in 3D tumor spheroid assays. Furthermore, NSH76 triggers nucleolar stress, leading to the activation of tumor suppressors p53 and p21. Notably, NSH76 does not induce DNA damage or mutagenicity. These findings establish NSH76 as a potent and selective Pol I inhibitor with significant therapeutic potential in cancer and possible implications for overcoming chemoresistance.


  • Open Access

    LINC01116-dependent upregulation of RNA polymerase I transcription drives oncogenic phenotypes in lung adenocarcinoma

    by Shashanka Shekhar Sarkar, Mansi Sharma, Sheetanshu Saproo, Srivatsava Naidu

    Hyperactive RNA Polymerase I (Pol I) transcription is canonical in cancer, associated with malignant proliferation, poor prognosis, epithelial-mesenchymal transition, and chemotherapy resistance. Despite its significance, the molecular mechanisms underlying Pol I hyperactivity remain unclear. This study aims to elucidate the role of long noncoding RNAs (lncRNAs) in regulating Pol I transcription in lung adenocarcinoma (LUAD). Bioinformatics analyses were applied to identify lncRNAs interacting with Pol I transcriptional machinery. Fluorescence in situ hybridization was employed to examine the nucleolar localization of candidate lncRNA in LUAD cells. RNA immunoprecipitation assay validated the interaction between candidate lncRNA and Pol I components. Chromatin isolation by RNA purification and Chromatin Immunoprecipitation (ChIP) were utilized to confirm the interactions of candidate lncRNA with Pol I transcriptional machinery and the rDNA core promoter. Functional analyses, including lncRNA knock-in and knockdown, inhibition of Pol I transcription, quantitative PCR, cell proliferation, clonogenicity, apoptosis, cell cycle, wound-healing, and invasion assays, were performed to determine the effect of candidate lncRNA on Pol I transcription and associated malignant phenotypes in LUAD cells. ChIP assays and luminometry were used to investigate the transcriptional regulation of the candidate lncRNA. We demonstrate that oncogenic LINC01116 scaffolds essential Pol I transcription factors TAF1A and TAF1D, to the ribosomal DNA promoter, and upregulate Pol I transcription. Crucially, LINC01116-driven Pol I transcription activation is essential for its oncogenic activities. Inhibition of Pol I transcription abrogated LINC01116-induced oncogenic phenotypes, including increased proliferation, cell cycle progression, clonogenicity, reduced apoptosis, increased migration and invasion, and drug sensitivity. Conversely, LINC01116 knockdown reversed these effects. Additionally, we show that LINC01116 upregulation in LUAD is driven by the oncogene c-Myc, a known Pol I transcription activator, indicating a functional regulatory feedback loop within the c-Myc-LINC01116-Pol I transcription axis. Collectively, our findings reveal, for the first time, that LINC01116 enhances Pol I transcription by scaffolding essential transcription factors to the ribosomal DNA promoter, thereby driving oncogenic activities in LUAD. We propose the c-Myc-LINC01116-Pol I axis as a critical oncogenic pathway and a potential therapeutic target for modulating Pol I transcription in LUAD.


  • Open Access

    Editorial: Role of non-coding RNAs (emphasis on the emerging role of circular RNAs) in cancer. Application potential for molecular diagnostics and therapeutics of cancer

    by Srivatsava Naidu, Srikanth Karnati, Harikrishnan Radhakrishnan, Anand Gupta

    Non-coding RNAs in cancer, circular RNAs (circRNA), long non-coding RNAs (lncRNA), microRNAs, cancer biology Editorial on the Research Topic Role of non-coding RNAs (emphasis on the emerging role of circular RNAs) in cancer. Application potential for molecular diagnostics and therapeutics of cancer Amidst the intricate genetic landscape of the human genome, a diverse array of noncoding RNAs (ncRNAs) has emerged as critical regulators of gene expression and cellular function (Nemeth et al., 2024). Among these, circular RNAs (circRNAs), microRNAs (miRNAs), and long non-coding RNAs (lncRNAs) form essential components of regulatory networks that govern cell fate in both normal and pathological contexts (Loganathan and Doss, 2023). There is substantial evidence that dysregulation of these ncRNAs is a hallmark of cancer. Notably, their distinct expression profiles hold immense potential for diagnosis, prognosis, and therapy, opening new avenues for molecular diagnostics and combinatorial treatments (Uppaluri et al., 2023). This editorial summarizes five high-impact review articles that delve into the pivotal advancements of ncRNAs in cancer research, addressing critical aspects of molecular oncology. Circular RNAs (circRNAs) are a unique class of non-coding RNAs, characterized by their covalently closed loop structures formed by back-splicing of primary transcripts (Zhang et al., 2020). CircRNAs regulate gene expression through various intricate mechanisms, including interactions with nucleic acids and proteins, and significantly influence gene expression at the epigenetic, transcriptional, post-transcriptional, and translational levels (Liu and Chen, 2022). CircRNAs are becoming increasingly important in cancer biology as they regulate key pathways involved in tumorigenesis, exhibit tumor-specific expression patterns, and demonstrate exceptional stability in tumors


  • Open Access

    The multifaceted roles of circular RNAs in cancer hallmarks: From mechanisms to clinical implications

    by Indira Kundu, Shivani Varshney, Srikanth Karnati, Srivatsava Naidu


  • Open Access

    Apoptosis-targeted gene therapy for non-small cell lung cancer using chitosan-poly-lactic-co-glycolic acid -based nano-delivery system and CASP8 and miRs 29A-B1 and 34A

    by Sourav Chattopadhyay, Shashanka Shekhar Sarkar, Sheetanshu Saproo, Sheetal Yadav, Deepika Antil, Bodhisatwa Das, Srivatsava Naidu

    Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths worldwide, with resistance to apoptosis being a major driver of therapeutic resistance and aggressive phenotype. This study aimed to develop a novel gene therapy approach for NSCLC by targeting resistance to apoptosis. Loss of function mutations of caspase 8 (CASP8) and downregulation of microRNAs (miRs) 29A-B1 and 34A were identified as key contributors to resistance to apoptosis in NSCLC. A biodegradable polymeric nano-gene delivery system composed of chitosan-poly-lactic-co-glycolic acid was formulated to deliver initiator CASP8 and miRs 29A-B1 and 34A. The nano-formulation efficiently encapsulated the therapeutic genes effectively internalized into NSCLC cells and induced significant apoptosis. Evaluation of the nano-formulation in A549 tumor spheroids showed a significant increase in apoptosis within the core of the spheroids, suggesting effective penetration into the spheroid structures. We provide a novel nano-formulation that demonstrate therapeutic potential for suicidal gene therapy in NSCLC.


  • Open Access

    Salivary protein kinase C alpha and novel microRNAs as diagnostic and therapeutic resistance markers for oral squamous cell carcinoma in Indian cohorts

    by Sheetanshu Saproo, Shashanka S. Sarkar, Vishakha Gautam, Chingmei W. Konyak, Gouri Dass, Arpita Karmakar, Mansi Sharma, Gaurav Ahuja, Anand Gupta, Juhi Tayal, et al.

    Oral squamous cell carcinoma (OSCC) is the second leading cause of cancer-related morbidity and mortality in India. Tobacco, alcohol, poor oral hygiene, and socio-economic factors remain causative for this high prevalence. Identification of non-invasive diagnostic markers tailored for Indian population can facilitate mass screening to reduce overall disease burden. Saliva offers non-invasive sampling and hosts a plethora of markers for OSCC diagnosis. Here, to capture the OSCC-specific salivary RNA markers suitable for Indian population, we performed RNA-sequencing of saliva from OSCC patients (n = 9) and normal controls (n = 5). Differential gene expression analysis detected an array of salivary RNAs including mRNAs, long non-coding RNAs, transfer-RNAs, and microRNAs specific to OSCC. Computational analysis and functional predictions identified protein kinase c alpha (PRKCA), miR-6087, miR-449b-5p, miR-3656, miR-326, miR-146b-5p, and miR-497-5p as potential salivary indicators of OSCC. Notably, higher expression of PRKCA, miR-6087 and miR-449b-5p were found to be associated with therapeutic resistance and poor survival, indicating their prognostic potential. In addition, sequencing reads that did not map to the human genome, showed alignments with microbial reference genomes. Metagenomic and statistical analysis of these microbial reads revealed a remarkable microbial dysbiosis between OSCC patients and normal controls. Moreover, the differentially abundant microbial taxa showed a significant association with tumor promoting pathways including inflammation and oxidative stress. Summarily, we provide an integrated landscape of OSCC-specific salivary RNAs relevant to Indian population which can be instrumental in devising non-invasive diagnostics for OSCC.


  • MiR-330-5p and miR-1270 target essential components of RNA polymerase I transcription and exhibit a novel tumor suppressor role in lung adenocarcinoma

    by Sheetanshu Saproo, Shashanka S. Sarkar, Ekta Gupta, Sourav Chattopadhyay, Aarzoo Charaya, Siddhant Kalra, Gaurav Ahuja, Srivatsava Naidu

    Upregulation of RNA polymerase I (Pol I) transcription and the overexpression of Pol I transcriptional machinery are crucial molecular alterations favoring malignant transformation. However, the causal molecular mechanism(s) of this aberration remain largely unknown. Here, we found that Pol I transcription and its core machinery are upregulated in lung adenocarcinoma (LUAD). We show that the loss of miRNAs (miR)-330-5p and miR-1270 expression contributes to the upregulation of Pol I transcription in LUAD. Constitutive overexpression of these miRs in LUAD cell lines suppressed the expression of core components of Pol I transcription, and reduced global ribosomal RNA synthesis. Importantly, miR-330-5p/miR-1270-mediated repression of Pol I transcription exerted multiple tumor suppressive functions including reduced proliferation, cell cycle arrest, enhanced apoptosis, reduced migration, increased drug sensitivity, and reduced tumor burden in a mouse xenograft model. Mechanistically, the downregulation of miR-330-5p and miR-1270 is regulated by Pol I subunit-derived circular RNA circ_0055467 and DNA hypermethylation, respectively. This study uncovers a novel miR-330-5p/miR-1270 mediated post-transcriptional regulation of Pol I transcription, and establish tumor suppressor properties of these miRs in LUAD. Ultimately, our findings provide a rationale for the therapeutic targeting of Pol I transcriptional machinery for LUAD.